. 2017 Dec 8;2017(1):298–303. doi: 10.1182/asheducation-2017.1.298

Table 1.

Selected recent studies treating PMBCL

Study	Treatment		Study type	Patient characteristics	Outcome
Study	Chemotherapy	RT±	Study type	Patient characteristics	Outcome
Savage et al²⁶	CHOP/R-CHOP /MACOP- B/VACOP-B	Variable	Retrospective study, N = 153	All IPI groups	At 5 y, PFS was 69%. Only MACOP-B/VACOP-B vs CHOP-like regimens were significantly different
Rieger et al²⁴	CHOP/R-CHOP	Variable, RT intended in 87%	Retrospective analysis, N = 87	Confined to AA-IPI of 0-1	At 3 y, EFS was 78% for R-CHOP and 52% for CHOP
Soumerai et al²⁵	R-CHOP	Yes, 77% of responding patients	Retrospective study, N = 63	All IPI groups	At 5 y, PFS was 68%
Dunleavy et al²⁸	DA-EPOCH-R	No	Prospective study, N = 51	All IPI groups	At 5 y, EFS was 93%
Martelli et al³¹	R-MACOP-B, R-VACOP-B, R-CHOP	Yes	Prospective study, N = 125	All IPI	Estimated 5 y PFS is 86%
Gleeson et al²⁷	R-CHOP-14 vs R- CHOP-21	Yes	Retrospective analysis, N = 50	Confined to stage I and II	5 y PFS, 79.8%

DA-EPOCH-R, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin, plus rituximab; EFS, event-free survival; IPI, international prognostic index; OS, overall survival; R-MACOP-B, rituximab and methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin; R-VACOP-B, rituximab with etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin.